Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 800 participants.

Also called NCT07414342

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 800 participants (planned count) (from the registry)
Sponsor
Beijing Balance Medical Technology Co., Ltd (from the registry)
Registry
  • NCT NCT07414342
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07414342. Allocation not applicable; no masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2027-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis
Condition
Severe Aortic Stenosis
Intervention (Device)
RENATUS® TAVR (transcatheter aortic valve replacement)
Lead sponsor
Beijing Balance Medical Technology Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07414342
Content hash
7a3c51bc5a6e020839587f7b97a7e3dff926f30a35644aec8b3c0a40c1501ce1